19 COMPARATIVE COST ANALYSIS OF ALTEPLASE VERSUS TENECTEPLASE FOR ISCHAEMIC STROKE IN A SINGLE CENTRE TERTIARY HOSPITAL

Abstract Background Stroke thombolysis has been a proven effective treatment for acute stroke since 1995. Since then Alteplase the standard thrombolytic agent used in hyperacute patient, dose being decided by body weight (0.9mg/kg). 10% of is given as bolus, and remaining 90% an infusion. As based, more than one vial can be required. Tenecteplase recent agent, 2017 large multi-centre randomised control trial NOR-TEST 2 indicated that similarly compared to Alteplase. entirely bolus dose, with maximum 40mg administered, equivalent vial. A single (Actilyse) costs €536, (Metalyse) €986. Our study was set up compare potential two treatments based on our patient cohort. Methods We retrospectively looked at patients ischaemic institution year 2019 (n=29). recorded number vials administer appropriate calculated cost over year, Tenectaplase, if were instead. Results Over course calendar 29 received All had requirement their admission weight, total €31,088 2019. The Tenectaplase same cohort would have €28,594, saving €2,494. Conclusion Based 2019, there benefit move towards using instead